Managing Lymphoma with Non-FDG Radiotracers: Current Clinical and Preclinical Applications

Table 2

The current available radiopharmaceuticals for radioimmunotherapy of lymphoma.

	^90Y-Zevalin	^131I-Bexxar	^131I-Rituximab
Radioisotope	^90Y; (𝑡1/2  =  2.67 days)	^131I; (𝑡1/2  =  8.01 days)	^131I; (𝑡1/2  =  8.01 days)
Anti-CD20 antibody	Ibritumomab tiuxetan	Tositumomab	Rituximab
Antibody type	Monoclonal murine	Monoclonal murine	Monoclonal chimeric
Predose injection	Unlabeled rituximab	Unlabeled tositumomab	Unlabeled rituximab
Pretherapy imaging	Yes (for biodistribution)	Yes (for dosimetry)	Yes (for dosimetry)
Pretherapy dose	^111In-Zevalin (5 mCi)	^131I-Bexxar (5 mCi)	^131I-Rituximab (5 mCi)
Treatment dose	0.4 mCi/kg (up to 32 mCi)	75 cGy (whole body)	75 cGy (whole body)